RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.6B
This Quarter Return
+5.31%
1 Year Return
+25.98%
3 Year Return
+194.74%
5 Year Return
+336.76%
10 Year Return
+2,199.29%
AUM
$2.63B
AUM Growth
+$2.63B
(-15%)
Cap. Flow
-$276M
Cap. Flow
% of AUM
-10.5%
Top 10 Holdings %
Top 10 Hldgs %
36.37%
Holding
119
New
10
Increased
38
Reduced
30
Closed
12
Top Buys
| 1 |
Scholar Rock
SRRK
|
$31M |
| 2 |
BPMC
Blueprint Medicines
BPMC
|
$28.6M |
| 3 |
Tenet Healthcare
THC
|
$16.3M |
| 4 |
Amicus Therapeutics
FOLD
|
$12.7M |
| 5 |
Janux Therapeutics
JANX
|
$10.9M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$59.8M |
| 2 |
Humana
HUM
|
$46.9M |
| 3 |
Exact Sciences
EXAS
|
$39.2M |
| 4 |
Neurocrine Biosciences
NBIX
|
$29.8M |
| 5 |
Align Technology
ALGN
|
$29.1M |
Sector Composition
| 1 | Healthcare | 97.94% |
| 2 | Consumer Staples | 1.85% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
argenx
ARGX
$43.6B
| $141M | 5.38% | 229,600 -3,900 | -2% | -$2.4M |
|
2
Intuitive Surgical
ISRG
$170B
| $113M | 4.29% | 216,000 -54,000 | -20% | -$28.2M |
|
3
Eli Lilly
LLY
$657B
| $112M | 4.25% | 144,500 +2,500 | +2% | +$1.93M |
|
|
4
Neurocrine Biosciences
NBIX
$13.8B
| $98.3M | 3.74% | 720,500 -218,500 | -23% | -$29.8M |
|
|
BPMC
5
DELISTED
Blueprint Medicines
BPMC
| $95.7M | 3.64% | 1,096,899 +328,123 | +43% | +$28.6M |
|
|
6
UnitedHealth
UNH
$281B
| $89M | 3.39% | 176,000 -118,250 | -40% | -$59.8M |
|
7
Travere Therapeutics
TVTX
$1.56B
| $86.6M | 3.3% | 4,973,649 +289,173 | +6% | +$5.04M |
|
8
Madrigal Pharmaceuticals
MDGL
$9.76B
| $81.8M | 3.12% | 265,212 +2,150 | +0.8% | +$663K |
|
9
Ultragenyx Pharmaceutical
RARE
$2.89B
| $73.2M | 2.79% | 1,739,813 -238,459 | -12% | -$10M |
|
10
Rhythm Pharmaceuticals
RYTM
$6.85B
| $65.1M | 2.48% | 1,162,718 -65,375 | -5% | -$3.66M |
|
11
Mirum Pharmaceuticals
MIRM
$3.71B
| $60.8M | 2.32% | 1,471,564 -108,924 | -7% | -$4.5M |
|
12
Alnylam Pharmaceuticals
ALNY
$58.5B
| $60.3M | 2.3% | 256,200 +6,200 | +2% | +$1.46M |
|
13
Penumbra
PEN
$10.6B
| $57M | 2.17% | 240,000 -25,000 | -9% | -$5.94M |
|
14
West Pharmaceutical
WST
$17.8B
| $55.3M | 2.1% | 168,750 +1,000 | +0.6% | +$328K |
|
15
Revolution Medicines
RVMD
$7.1B
| $53.1M | 2.02% | 1,213,257 +203,312 | +20% | +$8.89M |
|
16
Phreesia
PHR
$1.88B
| $51.3M | 1.95% | 2,040,000 -242,500 | -11% | -$6.1M |
|
17
Xenon Pharmaceuticals
XENE
$2.98B
| $49.1M | 1.87% | 1,251,859 -64,618 | -5% | -$2.53M |
|
18
Freshpet
FRPT
$2.72B
| $48.5M | 1.85% | 327,500 -119,000 | -27% | -$17.6M |
|
19
Ascendis Pharma
ASND
$11.8B
| $42M | 1.6% | 305,000 -20,000 | -6% | -$2.75M |
|
20
Kymera Therapeutics
KYMR
$2.95B
| $41.6M | 1.58% | 1,034,137 -15,249 | -1% | -$613K |
|
21
Boston Scientific
BSX
$156B
| $41.1M | 1.56% | 460,000 | – | – |
|
22
Edwards Lifesciences
EW
$47.8B
| $40.3M | 1.54% | 545,000 -31,900 | -6% | -$2.36M |
|
23
Insmed
INSM
$28.8B
| $38M | 1.45% | 550,000 -133,344 | -20% | -$9.21M |
|
24
Merus
MRUS
$4.98B
| $37.5M | 1.43% | 892,549 | – | – |
|
25
Sarepta Therapeutics
SRPT
$1.78B
| $37.4M | 1.42% | 307,500 | – | – |
|